Trial
NCT02257684
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jazz Pharmaceuticals
Collaborators
—
Condition
Acute Lymphoblastic Leukemia
Intervention
pegcrisantaspase
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-04